Literature DB >> 14763170

Carcinoma of the corpus uteri.

W T Creasman1, F Odicino, P Maisonneuve, U Beller, J L Benedet, A P Heintz, H Y Ngan, S Pecorelli.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14763170     DOI： 10.1016/s0020-7292(03)90116-0

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN： 0020-7292            Impact factor:   3.561


× No keyword cloud information.
  23 in total

1.  Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

2.  Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer.

Authors:  Kentaro Nakayama; Yutaka Nagai; Masako Ishikawa; Yoichi Aoki; Khoji Miyazaki
Journal:  Int J Clin Oncol       Date:  2010-04-24       Impact factor: 3.402

3.  How often does cervical involvement upstage patients with non-myoinvasive (otherwise stage 1A) endometrioid adenocarcinoma of the endometrium?

Authors:  Oluwole Fadare; Laurephile Desrosiers; Zhefu F Xiao; Sa A Wang
Journal:  Virchows Arch       Date:  2007-04-04       Impact factor: 4.064

4.  Salpingo-oophorectomy specimens for endometrial cancer staging: a comparative analysis of representative sampling versus whole tissue processing.

Authors:  Oluwole Fadare; Dineo Khabele
Journal:  Hum Pathol       Date:  2012-10-16       Impact factor: 3.466

5.  Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.

Authors:  Erica M Stringer; Gini F Fleming
Journal:  Oncol Hematol Rev       Date:  2013

6.  [Changes in the TNM classification of gynecological tumors].

Authors:  L-C Horn; M W Beckmann; A Beller; D Schmidt; U Ulrich; P Hantschmann; C Wittekind
Journal:  Pathologe       Date:  2010-09       Impact factor: 1.011

Review 7.  [Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed müllerian tumors. Facts and background].

Authors:  L-C Horn; K Schierle; D Schmidt; U Ulrich; A Liebmann; C Wittekind
Journal:  Pathologe       Date:  2011-05       Impact factor: 1.011

Review 8.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

9.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

10.  Conversion in endometrial cancer patients scheduled for laparoscopic staging: a large multicenter analysis: conversions and endometrial cancer.

Authors:  Stefano Palomba; Fabio Ghezzi; Angela Falbo; Vincenzo Dario Mandato; Gianluca Annunziata; Emilio Lucia; Antonella Cromi; Letizia Zannoni; Renato Seracchioli; Giorgio Giorda; Giovanni Battista La Sala; Fulvio Zullo; Massimo Franchi
Journal:  Surg Endosc       Date:  2014-07-09       Impact factor: 4.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.